Actively Recruiting
Study of Ziplyft Device for Removing Excess Eyelid Skin in Adults 35 and Older Evaluating Patient and Surgeon Satisfaction, Wound Healing, and Procedure Efficiency
Led by Osheru Inc. · Updated on 2025-08-27
200
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate patient and surgeon-reported outcomes for individuals undergoing blepharoplasty using a device called Ziplyft. The study focuses on measuring patient satisfaction with facial appearance and eyes, surgeon satisfaction and efficiency, bruising, eyelid symmetry, wound closure success with tissue adhesive, and case time. The study is interventional and monitors these outcomes over a 3-month period following the procedure. Participants will receive treatment with Ziplyft, a Class 1, 510k exempt device designed to remove excess unwanted eyelid skin through a novel surgical method. The procedure is performed once, followed by regular follow-up visits extending up to 3 months to assess various outcomes including the success of wound closure and improvements in eyelid appearance and symmetry. Throughout the study, participants will attend scheduled visits for evaluations that include patient and surgeon feedback, assessments of bruising and eyelid symmetry, and measurements related to wound healing and procedure efficiency. Researchers will track these factors from enrollment through the final visit at 3 months to understand the devices performance and participant satisfaction. Participants are also monitored for any adverse effects and are expected to comply with study instructions and follow-up visits during this time.
CONDITIONS
Brief Title
Evaluating Patient Reported Outcomes and Surgeon Satisfaction With Ziplyft™
Research Team
P
Patricia Buehler, MD
B
Becky Weathers
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here